Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel - Sanofi

Drug Profile

Cabazitaxel - Sanofi

Alternative Names: 116 258; Jevtana; RPR 116258; RPR 116258A; Taxoid-116258; TXD 258; XRP6258

Latest Information Update: 19 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; SCRI Development Innovations; Sidney Kimmel Cancer Center; University Hospitals Bristol NHS Foundation Trust
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell and embryonal neoplasms; Liposarcoma; Penile cancer; Small cell lung cancer; Urogenital cancer
  • Phase I/II Solid tumours
  • No development reported Gastric cancer; Head and neck cancer

Most Recent Events

  • 19 Jun 2019 Sanofi terminates the phase-II PRIMCAB trial in Prostate cancer (Metastatic disease, Second-line therapy or greater) in USA and Canada due to unsatisfactory patient accrual (IV) (NCT02379390)
  • 04 Jun 2019 University of California and Sanofi completes a phase II trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (IV) (NCT02844582)
  • 01 Apr 2019 Genzyme initiates enrolment in a phase II trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Canada (NCT03764540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top